[Infection due to Mycobacterium malmoense in an immunocompetent patient]. 2008

B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
Service de Pneumologie, Centre Hospitalier Général d'Albi, Albi, France. camara.b@chu-toulouse.fr

BACKGROUND Mycobacterium malmoense (MM) is an atypical mycobacterium responsible for opportunistic infection. The clinical and radiological picture is non-specific. The infection develops most frequently in a dystrophic lung. METHODS A patient of 52 years was admitted with an extensive multifocal pneumonia which later proved to be due to infection with MM. Empirical treatment was started with the combination of rifampicin, isoniazid, pyrazinamide (rifater) and ethambutol (myambutol). Subsequently, cultures showed sensitivity to rifampicin, ethambutol, oxfloxacin, clarithromycin (MIC < 2 mg/l) and rifabutin (MIC < 0.5 mg/l). More than two weeks after the start of treatment, material aspirated at fibroscopy showed the persistence of numerous acid-alcohol fast bacilli, an increase, compared with the original examination, from 5 to 25 per field on day 2, to 20 to 100 per field on day 19. Despite the late addition of clarithromycin there was a progressive deterioration in the pulmonary condition. CONCLUSIONS There is little correlation between the in vivo and in vitro sensitivities of MM to antibiotics. In our patient the progress was unfavourable, even though the mycobacterium was sensitive to the combination of antibiotics used, with the exception of isoniazid that was not tested. In vitro isoniazid does not seem to be active against MM. There is no consensus of opinion on the antibiotic treatment of MM infections.

UI MeSH Term Description Entries
D007121 Immunocompetence The ability of lymphoid cells to mount a humoral or cellular immune response when challenged by antigen. Competence, Immunologic,Immunologic Competence,Immunological Competence,Competence, Immunological
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009165 Mycobacterium Infections, Nontuberculous Infections with nontuberculous mycobacteria (atypical mycobacteria): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae, M. leprae. Mycobacterium Infections, Atypical,Atypical Mycobacterial Infection, Disseminated,Atypical Mycobacterial Infection, Familial Disseminated,Atypical Mycobacteriosis, Familial,Atypical Mycobacteriosis, Familial Disseminated,Atypical Mycobacterium Infections,Infections, Atypical Mycobacterium,Mycobacterium abscessus Infection,Atypical Mycobacterium Infection,Familial Atypical Mycobacterioses,Familial Atypical Mycobacteriosis,Infection, Mycobacterium abscessus,Infections, Mycobacterium abscessus,Mycobacterioses, Familial Atypical,Mycobacteriosis, Familial Atypical,Mycobacterium Infection, Atypical,Mycobacterium Infection, Nontuberculous,Mycobacterium abscessus Infections,Nontuberculous Mycobacterium Infection,Nontuberculous Mycobacterium Infections
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D018410 Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections. Bacterial Pneumonia,Bacterial Pneumonias,Pneumonias, Bacterial
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
January 2009, Revue medicale de Liege,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
February 2001, Annales de dermatologie et de venereologie,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
April 2005, Pneumologie (Stuttgart, Germany),
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
July 2015, Tuberculosis and respiratory diseases,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
March 1993, The Journal of infection,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
January 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
September 2012, Oral and maxillofacial surgery,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
March 1990, International journal of dermatology,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
September 1998, Journal of the European Academy of Dermatology and Venereology : JEADV,
B Camara, and B Borrel, and G Panteix, and J-M Merault, and M Vialas, and A Sanchez, and P Massip, and P Barel
January 1997, Respiration; international review of thoracic diseases,
Copied contents to your clipboard!